We further illustrated its potency in inhibiting ANGPTL3-mediated LPL activity in vitro, lipid-reducing function in hypercholesterolemic mice, as well as ameliorating efficacy in NAFLD mice, indicating that the C44-Fc could be a potent therapeutic candidate for NAFLD. Here, ANGPTL3 is linked to metabolic dysfunction-associated steatotic liver disease.